Price
2,043.8
+1.13%52W Range
Market Cap
₹12,499.90 Cr
Traded: ₹4.92 Cr (0.04%) 0.0x
Free Float: ₹2,718.73 Cr (0.18% of FF traded)
Volume · 60D trend
24.19 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | -- | +17.0% | -- | +17.0% | Stable |
| Profit | -- | -- | +33.0% | -- | +33.0% | Stable |
| Return | -- | -- | -- | -- | -- | -- |
| ROE | -- | -- | +27.0% | -- | -- | -- |
Quarterly Results
Jun 2025
Mar 2025
Dec 2024
Sep 2024
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 422 | 353 | 342 | 361 | 347 | 294 | 298 | 314 |
| Expenses | 329 | 291 | 259 | 283 | 277 | 239 | 228 | 247 |
| Operating Profit | 93 | 62 | 83 | 78 | 70 | 54 | 69 | 67 |
| Other Income | 3 | 4 | -17 | 2 | 2 | 2 | 1 | 2 |
| Interest | 3 | 1 | 2 | 2 | 2 | 2 | 2 | 3 |
| Depreciation | 13 | 10 | 9 | 9 | 9 | 10 | 10 | 9 |
| Profit Before Tax | 80 | 55 | 55 | 70 | 61 | 44 | 58 | 57 |
| Tax % | 25.0% | 17.0% | 25.0% | 25.0% | 24.0% | 28.0% | 23.0% | 25.0% |
| Net Profit | 60 | 45 | 41 | 52 | 46 | 32 | 45 | 43 |
| Exceptional Items | 0 | 0 | -19 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 9.8 | 7.4 | 6.8 | 8.6 | 7.5 | 5.2 | 7.3 | 7.0 |
| Sales Growth (YoY) | 21.9% | 20.2% | 15.0% | 15.1% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -- | 3.2% | -5.3% | 4.0% | 18.0% | -1.3% | -5.1% | -- |
| OP Growth (YoY) | 32.9% | 14.8% | 20.3% | 16.4% | -- | -- | -- | -- |
| OP Growth (QoQ) | 50.0% | -25.3% | 6.4% | 11.4% | 29.6% | -21.7% | 3.0% | -- |
| Profit Growth (YoY) | 30.0% | 44.0% | 21.0% | 22.0% | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | 43.6% | -8.2% | 21.6% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 9.8% | -21.1% | 13.3% | 46.3% | -29.8% | 4.5% | -- |
| OP Margin | -- | 17.6% | 24.3% | 21.6% | 20.2% | 18.4% | 23.1% | 21.3% |
| Net Margin | -- | 12.8% | 12.0% | 14.4% | 13.3% | 10.9% | 15.1% | 13.7% |
| Material Cost % | 18.4% | 18.8% | 17.6% | 19.0% | 19.0% | 19.4% | 18.5% | 19.9% |
| Employee Cost % | 28.9% | 30.2% | 28.0% | 28.5% | 28.1% | 28.9% | 30.1% | 28.0% |
| P/S | 8.45 | 9.15 | 7.77 | -- | -- | -- | -- | -- |
| P/E | 62.81 | 69.36 | 56.70 | -- | -- | -- | -- | -- |
| P/B | 16.73 | 17.18 | 15.89 | -- | -- | -- | -- | -- |
Exchange Filings
50Press Release on GMP Compliance Certification from Brazilian Health Regulatory Agency, ANVISA, Brazil
Intimation regarding receipt of GMP Compliance Certification from Brazilian Health Regulatory Agency, ANVISA, Brazil for OSD manufacturing facility and Hormone manufacturing facility of ....
Intimation for Schedule of Analyst / Investor Conference
Corona Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026
Credit Rating
Intimation of Closure of Trading Window
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sepia Investments Ltd, Sage Investment Trust ....
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sepia Investments Ltd, Sage Investment Trust ....
Intimation of participation in Analyst / Investor meet
Reply to Clarification
The Exchange has sought clarification from Corona Remedies Ltd on September 10, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.
Intimation of participation in Analyst / Investor Conference
Transcript of Earnings Call with Analyst / Investor on Unaudited Financial Results for the first quarter and three months ended June 30, 2026
Intimation for Schedule of Analysts / Investor Conference
Unaudited Financial Results for the first quarter and three months ended June 30, 2026
Intimation for Schedule of Analysts / Investor Conference
Corona Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Declaration of Voting Results and Scrutinizer''s Report for 22nd Annual General Meeting
Outcome of 22nd Annual General Meeting
Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the first quarter ended June 30, 2026
Intimation under Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015-Commencement of Commercial Production
Press Release for Commencement of Commercial Production
Intimation of Closure of Trading Window for dealing in securities of CORONA Remedies Limited in terms of SEBI (Prohibition of Insider Trading) Regulations, 2015
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sepia Investments Ltd & Others
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sepia Investments Ltd & Others
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Invesco Mutual Fund
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Invesco Mutual Fund
Newspaper Publication - Notice of 22nd Annual General Meeting , Intimation of Record Date and E-voting information
Annual Report 2025-26
Communication to Shareholders - Annual Report 2025-26
Business Responsibility and Sustainability Reporting for the F.Y. 2025-26
Annual Report for the F.Y. 2025-26
Notice of 22nd Annual General Meeting scheduled to be held on Thursday, July 09, 2026
Intimation for Schedule of Analysts / Investor Conference
Newspaper Publication - Intimation of 22nd Annual General Meeting of the Company through Video Conferencing / Other Audio Visual Means (VC / OAVM) facility
Intimation for Non-Deal Roadshow
Press Release - Receipt of EU-GMP Certification
Communication to Shareholders - Intimation on Tax Deduction on Dividend
Intimation of participation in Analyst / Investor Conference
Transcript of Earnings call with Analyst/Investor on Financial Results for the fourth quarter and year ended March 31, 2026
Newspaper Publication of Audited Financial Results for the fourth quarter and year ended on March 31, 2026.
Audio Recording of conference call with Analyst / Investor on Financial Results for the fourth quarter and year ended March 31, 2026
Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026
Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026
Board at its meeting held today, i.e. May 11, 2026 has, inter alia, considered and approved the following: (i) audited Standalone and Consolidated Financial Results along with Audit Reports ....
Re-appointment of Dr. Kirtikumar Mehta (DIN: 00385658) as the Non Executive Director and Chairman of the Company for the term of five consecutive Financial Years with effective from April 01, 2027
Re-appointment of M/s. Manish B. Analkat as the Cost Auditor of the Company for F.Y. 2026-27
Re-appointment of M/s. Dhara Patel, peer reviewed Company Secretary Firm as the Secretarial Auditor of the Company for five financial years commencing from F.Y. 2026-27
Appointment of M/s. Shah & Shah Associates, Chartered Accountants as Internal Auditor of the Company for the F.Y. 2026-27
Credit Ratings
1Concalls
2Feb 2026
28 Feb 2026Jan 2026
31 Jan 2026Held by ETFs
2 ETFs hold CORONA · sorted by weight
Held by Mutual Funds
34 schemes hold CORONA · sorted by weight